Roche Hanmi Pharm $2.3B License — Deal Structure Breakdown

Roche Hanmi Pharm $2.3B License — Deal Structure Breakdown

$190 million upfront for a Phase 1 peptide targeting urocortin 2 receptor — that is the price Roche just paid to license HM17321 from Hanmi Pharm in a deal announced August 24, 2026, with a total potential value of $2.3 billion. The Hanmi Pharm Roche deal terms include $2.1 billion in development, regulatory, and commercial milestones, with royalty rates undisclosed. This is the clearest signal yet that Big Pharma views muscle-sparing metabolic mechanisms as the next frontier beyond incretin-based obesity drugs — and is willing to pay Phase 2–level economics for Phase 1 assets that credibly address muscle loss alongside fat metabolism.

Deal Structure Breakdown

The Hanmi Pharm Roche deal structure breaks down into three layers. Let's dissect each one.

Upfront-to-TDV Ratio: 8.3%

An 8.3% upfront-to-TDV ratio for a Phase 1 asset is above the median for early-stage metabolic licenses. Across comparable Phase 1 metabolic deals tracked in metabolic deal benchmarks, the median upfront-to-TDV ratio sits around 5–7%. Roche's willingness to pay $190M — roughly 120–150 basis points above the median — reflects two things: first, Hanmi's leverage as a proven peptide engineering platform with a track record of large out-licensing deals (the Hanmi-Sanofi efpeglenatide deal and the Hanmi-Janssen lazertinib precedent); second, genuine competitive tension around differentiated metabolic mechanisms.

Milestone Stack: $2.1 Billion

The $2.1 billion milestone stack is heavily back-loaded. While neither party disclosed the exact split, the structure is consistent with a deal where roughly 40% of milestones are tied to development and regulatory events (Phase 2 data readout, Phase 3 initiation, Phase 3 topline, FDA filing, FDA approval, EMA approval) and 60% are tied to commercial thresholds (likely tiered at $500M, $1B, $2B, and $5B in annual net sales). This back-loading is standard for Phase 1 deals but the absolute magnitude is not. A $2.1 billion milestone package for a Phase 1 metabolic peptide puts HM17321 in the top decile of comparable transactions. Run the numbers yourself on Solidus — most Phase 1 peptide out-licenses in metabolic disease carry total milestones in the $400M–$900M range.

Royalties: Undisclosed but Estimable

Royalties were not disclosed. For a Phase 1 license in metabolic disease from an originator with Hanmi's profile — strong IP position, proprietary LAPSCOVERY platform, no co-development or co-commercialization rights retained — the likely range is low-to-mid double digits. Comparable precedents suggest 10–15% on net sales, tiered upward. The undisclosed status itself is informative: Roche typically discloses royalty ranges in its press releases when they are in single digits. The silence here implies rates that are competitively favorable to Hanmi.

Competitive Context — Why Roche and Why HM17321

Roche has a metabolic pipeline problem, and the Hanmi Pharm Roche deal terms are a direct response to it. While Novo Nordisk, Eli Lilly, Amgen, and Viking Therapeutics have dominated the obesity and metabolic headlines with GLP-1 and GLP-1/GIP dual agonists, Roche's internal metabolic portfolio has been conspicuously thin. The CT-388 asset Roche acquired through its $2.7B buyout of Carmot Therapeutics in late 2023 gave it a GLP-1/GIP entry, but that alone does not differentiate Roche in a market rapidly heading toward saturation at the incretin level.

HM17321 fills a fundamentally different gap. Its mechanism — a urocortin 2 analog activating a pathway that spurs muscle growth and fat metabolism simultaneously — is orthogonal to the incretin mechanism. This matters enormously. The single biggest clinical and commercial criticism of current GLP-1 agonists is lean muscle mass loss. Patients on semaglutide and tirzepatide lose 25–40% of their total weight as lean mass, creating long-term sarcopenia risks and limiting drug durability. A molecule that promotes fat loss while preserving or building muscle is not a nice-to-have; it is the next $50B therapeutic category.

Why Hanmi Specifically

Hanmi's LAPSCOVERY platform gives it a structural advantage in peptide half-life extension. The company has demonstrated this across multiple assets: efpeglenatide (long-acting GLP-1, licensed to Sanofi), efinopegdutide (GLP-1/glucagon, licensed to MSD), and now HM17321. Roche is not just buying a molecule — it is buying validation that the urocortin 2 peptide can be engineered into a viable drug-like candidate with acceptable PK. That platform de-risking is worth a premium.

Timing Drivers

The timing is not coincidental. Three dynamics converged:

• Clinical readouts from muscle-sparing competitors: BioAge's azelaprag failed in Phase 2 in early 2025, reducing the competitive field. Scholar Rock's apitegromab showed mixed results in SMA-related muscle wasting but validated the muscle biology thesis. The field is thinning, and HM17321 enters with a differentiated mechanism and less direct competition.
• Lilly's dual-threat positioning: Eli Lilly's bimagrumab + semaglutide combination data, showing meaningful lean mass preservation, put every competitor on notice. Roche needed a proprietary answer, not a combination strategy dependent on someone else's GLP-1.
• Hanmi's leverage window: With multiple metabolic assets in or nearing the clinic, Hanmi was fielding inbound interest from at least three large-cap pharma companies. Roche's $190M upfront was the cost of preempting a competitive process that would have only driven terms higher.

What This Means for Similar Assets

If you are a biotech founder or BD lead holding a Phase 1 peptide asset in metabolic disease, the Hanmi Pharm Roche deal structure just reset your valuation expectations — with caveats.

Upfront Benchmarks

For a Phase 1 metabolic peptide with a differentiated (non-incretin) mechanism and credible preclinical data, the new floor for upfront payments from a top-10 pharma licensee is $100M–$200M. Before this deal, the realistic range was $50M–$120M. The Hanmi-Roche deal pushes the ceiling meaningfully. However, this premium is specific to assets with two characteristics: (1) a mechanism that addresses muscle preservation or body composition, and (2) a platform-validated peptide with demonstrated half-life extension. Generic early-stage peptides without these differentiators will not command HM17321 economics.

Total Deal Value

TDVs above $2B for Phase 1 metabolic assets are now established precedent, not outliers. The Amgen-Nxera $1.8B deal, the AstraZeneca-Eccogene $1.6B deal, and now the Hanmi-Roche $2.3B deal form a clear trend line. Phase 1 metabolic peptides with novel MOAs are being valued at 2–4x the levels seen in 2022–2023. Check metabolic deal benchmarks for the full historical distribution.

Royalty Expectations

With royalties undisclosed in this deal, the best proxy remains the Hanmi-Sanofi efpeglenatide terms (reported as low double digits) and the broader Phase 1 peptide licensing median of 8–14% tiered. If your asset has genuine differentiation and you are negotiating with a buyer who faces competitive urgency, push for 12–15% base rates with escalators. The market supports it.

Strategic Positioning Advice

The single most important takeaway: Big Pharma is now willing to pay Phase 2 economics for Phase 1 metabolic assets that credibly address muscle preservation. If your pipeline includes a muscle-sparing mechanism — whether via urocortin, myostatin/activin, or another pathway — your BD timeline should accelerate. The window of peak buyer urgency is open now. It will narrow as more clinical data emerges and differentiation becomes harder to claim on preclinical data alone.

Benchmark your own metabolic deal against 1,600+ comparable transactions using the Ambrosia calculator. Get custom upfront, milestone, and royalty comps by phase, modality, and therapeutic area in under 60 seconds.